Table 5 Previous MCTKD clinical studies
Study | n | Age (years) | MCT energy ratio | Duration (months) | Responder rate | Seizure freedom rate | Side effects |
|---|---|---|---|---|---|---|---|
Huttenlocher et al., 1971 [4] | 12 | 2.5–16 | 60% | 2.5–13 | 66.7% | 50% | 41.7% |
Trauner, 1985 [7] | 17 | 1–13 | 60% | 2–60 | 58.8% | 29.4% | 29.4% |
Sills et al., 1986 [8] | 50 | 2–15 | 45–60% | 6–48 | 50.0% | 18.2% | - |
Schwartz et al., 1989 [10] | 12 27 | 5–54 | 30% 60% | 1.5–48 | 66.7% 81.7% | - | ~ half |
Liu, 2008 [12] | 43 | 2–16 | 40–55% 60% > 60% | - | 82% | 21% | - |
Neal et al., 2009 [5] | 72 | 2–16 | 40–45% | 12 | 29.2%, 19.4%, and 22.2% at 3, 6, and 12 months | - | - |
Chomtho et al., 2016 [13] | 16 | 0.5–16 | 50% | 3 | 50%, and 64.3% at 1 and 3 months | 6.25%, and 28.6% at 1 and 3 months | 80% |
Lowe et al., 2022 [6] | 17 | 4.0–8.5 | 40–50% | 6 | 58.8% | - | 82.4% |